Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Biohimik
Saransk, Republic of Mordovia, Russiabiohimik.ru ↗
- Ownership
- Private
- Employees
- ~1500
- Development stage
- Other
01
Overview
Biohimik is a prominent Russian pharmaceutical manufacturer and a primary production site for the Promomed Group. Located in Saransk, the company was established in 1952 and was one of the first facilities in the USSR to produce penicillin. Today, it specializes in the full-cycle production of essential medicines, including antibiotics, antivirals, and endocrinology products. The company is notably recognized for its role in developing and manufacturing the COVID-19 treatment Areplivir (favipiravir). Biohimik maintains extensive GMP-certified manufacturing capabilities and operates a dedicated R&D center for drug synthesis and formulation development.
- Therapeutic areas
- EndocrinologyCardiovascularNeurologyInfectious DiseasesOncology
- Modalities
- Small moleculeBiologicPeptides
- Industry
- Biotech
Beyond the preview
Go deeper on Biohimik.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biohimik.